A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
Claudia Arce, Carlos Pérez-Plasencia, Aurora González-Fierro et al. · 2006
Read A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer by Claudia Arce, Carlos Pérez-Plasencia, Aurora González-Fierro et al. (2006) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0000098.txt.
Description
Claudia Arce, Carlos Pérez-Plasencia, Aurora González-Fierro, and their team ran an early clinical test in breast cancer in PLOS ONE in 2006. Epigenetic therapy uses drugs that switch silenced genes back on. The team added such therapy to standard chemotherapy given before surgery for locally advanced tumors.
A proof-of-principle study checks whether an idea works at all in patients, before large trials. The authors report the combined treatment could be given and showed signs of activity against the tumors. That green light is the true product of a small study like this. It justifies the cost and effort of proper trials to learn whether the benefit is real.
Catalog record
| CREATOR | Claudia Arce, Carlos Pérez-Plasencia, Aurora González-Fierro et al. |
|---|---|
| YEAR | 2006 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000098